Systemic treatment for hepatocellular carcinoma beyond milan criteria on the waitlist: is it time for a neoadjuvant therapy?

References

[1] Mazzaferro V,Doci R.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med1996; 334:693-700

[2] Yao FY,Bass NM.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.Hepatology2001;33:1394-403

[3] Bruix J,Galle PR,Sangro B.Systemic treatment of hepatocellular carcinoma: an EASL position paper.J Hepatol2021;75:960-74

[4] Cabibbo G,Lai Q.Italian Association for the Study of the Liver (AISF)Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.Dig Liver Dis2022;54:452-60

[5] Mazzaferro V,Bhoori S.Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.Lancet Oncol2020;21:947-56

[6] Jeng KS,Chung CS.Transplantation after successful downstaging by multimodal treatments of american joint committee on cancer stage IIIB hepatocellular carcinoma with portal vein thrombi: a case Report.Transplant Proc2018;50:2882-4.

[7] Ho CM,Hu RH.Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.Ther Adv Med Oncol2019;11:1758835919843463. PMCID:PMC6487770

[8] Gassmann D,Mertens JC.Liver allograft failure after nivolumab treatment-a case report with systematic literature research.Transplant Direct2018;4:e376. PMCID:PMC6092180

[9] Tabrizian P,Schwartz ME.PD-1 inhibitor as bridge therapy to liver transplantation?.Am J Transplant2021;21:1979-80.

[10] Schwacha-Eipper B,Banz V.Immunotherapy as a downstaging therapy for liver transplantation.Hepatology2020;72:1488-90